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Background: The U.S. National Institute of Allergies and Infectious Diseases (NIAID) and the National Institute of
Mental Health (NIMH) have a new research priority: inclusion of terminally ill persons living with HIV (PLWHIV) in HIV
cure-related research. For example, the Last Gift is a clinical research study at the University of California San Diego
(UCSD) for PLWHIV who have a terminal illness, with a prognosis of less than 6 months.
Discussion: As end-of-life (EOL) HIV cure research is relatively new, the scientific community has a timely opportunity
to examine the related ethical challenges. Following an extensive review of the EOL and HIV cure research ethics
literature, combined with deliberation from various stakeholders (biomedical researchers, PLWHIV, bioethicists, and
socio-behavioral scientists) and our experience with the Last Gift study to date, we outline considerations to ensure
that such research with terminally ill PLWHIV remains ethical, focusing on five topics: 1) protecting autonomy through
informed consent, 2) avoiding exploitation and fostering altruism, 3) maintaining a favorable benefits/risks balance, 4)
safeguarding against vulnerability through patient-participant centeredness, and 5) ensuring the acceptance of next-of-
kin/loved ones and community stakeholders.
Conclusion: EOL HIV cure-related research can be performed ethically and effectively by anticipating key issues that
may arise. While not unique to the fields of EOL or HIV cure-related research, the considerations highlighted can help
us support a new research approach. We must honor the lives of PLWHIV whose involvement in research can provide
the knowledge needed to achieve the dream of making HIV infection curable.
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Due to the development of highly effective antiretroviral
therapy (ART), persons living with HIV (PLWHIV) are liv-
ing longer [1–3]. In the United States, half of PLWHIV will
be 50 years or older by the year 2020 [3]. Considered an
almost certain death sentence in the 1980s, HIV/AIDS has
now become a manageable chronic condition. PLWHIV
increasingly die of causes mirroring those in the general
population [4]. Despite this, HIV persists throughout the
body [5] and a global effort is underway to find a cure for
the infection [6].* Correspondence: karine_dube@med.unc.edu
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therapeutic intervention or approach that controls or
eliminates HIV infection to the point that no further med-
ical interventions are needed to maintain health; and 2)
preliminary scientific concepts that might ultimately lead
to such a therapeutic intervention [7].” HIV cure or remis-
sion research includes both observational assessments,
such as the measurement and characterization of HIV res-
ervoirs, and interventional approaches, including early
ART, latency-reversing agents, immune-based strategies,
gene editing or modification, stem cell transplantation, or
combination approaches [6]. While most HIV cure-related
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of PLWHIV who are terminally ill [9, 10]. End-of-life
(EOL) HIV cure research is currently limited to observa-
tional assessments at one clinical research site in the
United States: The University of California, San Diego
(UCSD). The purpose of this research is to investigate
HIV reservoirs and does not involve palliative care re-
search. EOL HIV cure-related research may soon be ex-
panded to include additional clinical research sites
throughout the U.S. and to involve interventional HIV
cure-related approaches, such as broadly neutralizing anti-
bodies and other interventions with a favorable benefit/
risk assessment. This research does not benefit partici-
pants physically, but seeks to produce generalizable scien-
tific knowledge towards an HIV cure or virologic
suppression off therapy.
While clinical research with participants at the end of
life is not a new phenomenon [11, 12], the utilization of
this model in the setting of HIV cure research is novel.
Since EOL HIV cure research is relatively new, the scien-
tific community has a timely opportunity to examine
ethical challenges associated with this type of research.
Our paper is rooted in the ethics of conducting clinical
research at the EOL [11, 12], and builds on an emerging
HIV cure research ethics literature [13–15]. Following
an extensive review of the EOL and HIV cure research
ethics literature, combined with deliberation from vari-
ous stakeholders (biomedical researchers, PLWHIV, bio-
ethicists, socio-behavioral scientists and Community
Advisory Board members of the AntiViral Research Cen-
ter at UCSD, the Palm Springs HIV and Aging Research
Project and the Palm Springs Positive Life Program), as
well as our experience in the Last Gift study to date, we
describe possible ethical considerations for the design,
conduct, review and evaluation of HIV cure-related re-
search with terminally ill PLWHIV. After describing
EOL HIV cure-related research at UCSD [10] and identi-
fying ethical issues for clinical research at the EOL, we
review topics relevant to HIV cure-related research with
terminally ill PLWHIV.
We outline considerations to ensure that such research
remains ethical, focusing on five domains: 1) protecting
autonomy through informed consent, 2) avoiding exploit-
ation and fostering altruism, 3) maintaining a favorable
benefits/risks balance, 4) safeguarding against vulnerability
through patient-participant centeredness, and 5) ensuring
the acceptance of next-of-kin/loved ones and community
stakeholders. We conclude by summarizing ethical con-
siderations for HIV cure-related research at the EOL.Fig. 1 The Last Gift logo was designed by Andy Kaytes, HIV activist
and chair of the AntiViral Research Center Community Advisory
Board. Each piece of the puzzle represents one Last Gift participantThe Last Gift study
The Last Gift is a clinical research study at UCSD for
PLWHIV who have a terminal illness, such as a solidorgan cancer, advanced heart disease, or neurodegen-
erative disease (e.g., amyotrophic lateral sclerosis
(ALS)), and have a prognosis of living less than 6
months, as determined by their physician (Fig. 1)
[10]. Approximately 30 Last Gift study participants
will be recruited on the basis of their voluntary
altruistic motivations to donate their blood and other
samples (ante-mortem) and bodies (post-mortem) to
advance HIV cure science. Ante-mortem procedures
involve basic blood draws and optional collection of
genital secretions and rectal swabs to characterize cel-
lular reservoirs of HIV, concurrently with in-depth
socio-behavioral sciences questionnaires to assess
experiences and feelings about EOL HIV cure-related
research participation. Post-mortem procedures in-
clude methodical characterization of the size, distri-
bution, activity and mechanisms of HIV reservoirs
throughout the body (including blood, brain, genital
tract, gut and other deep tissues), based on a rapid
research autopsy performed within 6 h of death. If a
research autopsy is not performed within 6 h of
death, virus and cells degrade and the physiology
changes [16]. Answers may inevitably be lost as to
why HIV persists in cells and tissues. If Last Gift
participants elect to interrupt their HIV treatment
before death, the study team will characterize
rebounding HIV ribonucleic acid (RNA) populations.
In general, HIV cure science can potentially benefit
from a peri-mortem human research model by
allowing laboratory-based technologies – including
genomics, proteomics, and metabolomics – to eluci-
date how HIV persists in deep tissues with or
without ART.
The choice of studying terminally ill volunteers living
with HIV was motivated by: 1) the absence of any rea-
sonable expectation of direct clinical benefits in most
HIV cure research, 2) the manifest desire in this commu-
nity to ‘give back’ to the HIV research field [17], 3) lim-
ited opportunities for terminally ill PLWHIV to
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the fact that people at the EOL may be willing to
accept higher risks for research participation, 5) the
possibility for donating their full body for a rapid
research autopsy, and 6) the opportunity to create a new
translational research model to advance HIV cure science
(e.g. to test novel HIV cure-related interventions in a
human model).
Engagement efforts and preliminary acceptability
research in Southern California revealed that EOL
HIV cure-related research is widely accepted in the
local community [19]. This is likely because many
older adults living with HIV have survived an
epidemic that was once untreatable [3]. Similarly,
cancer research has benefited from peri-mortem and
rapid autopsy research programs, providing a better
understanding of cancer mechanisms and how various
oncology drugs have affected these cellular mecha-
nisms [16, 20]. Providing an opportunity for termin-
ally ill persons to make important contributions to
science is aligned with the principle of distributive
and representational justice [11].Ethical principles for clinical research at the EOL
Most HIV cure-related studies consist of observational
assessments to better understand HIV reservoirs in the
body or proof-of-concept experiments with no expect-
ation of direct clinical benefit [21]. The aims of these
studies are to obtain generalizable knowledge and iden-
tify novel approaches to cure disease [22, 23]. EOL HIV
cure-related research faces many of the same ethical
challenges surrounding early-phase research, such as the
need to ensure social value and scientific validity of the
study, to carefully assess risks, and to ensure voluntary
and informed consent [24, 25]. In their seminal article
‘What makes clinical research ethical?’ [26], Emanuel
and colleagues outlined seven requirements that
provide a strong ethical foundation for clinical
research. Their ethical framework was drawn by syn-
thesizing the literature on the ethics of research in-
volving human participants, including the Nuremberg
Core (1947), the Declaration of Helsinki (1964, 1975,
1983, 1989, 1996), the Belmont Report (1979) and the
International Ethical Guidelines for Biomedical Re-
search Involving Human Subjects (1982, 1993), among
others. The seven requirements include: 1) social and
scientific value; 2) scientific validity; 3) favorable
risk-benefit ratio; 4) informed consent (autonomous
choice); 5) respect for participants; 6) fair selection of
research participants; 7) independent review. In this
paper, we emphasize the first five requirements. In
the EOL research context, the principles of social
value and scientific progress are paramount, becauseresearch participants will have already died by the
time scientific findings materialize [27].
Using an approach similar to Emanuel et al., Lo and
Grady emphasized eight ethical considerations for the
field of HIV cure-related research: 1) collaborative part-
nership; 2) social value; 3) scientific validity; 4) fair selec-
tion of participants; 5) favorable risk-benefit balance; 6)
independent review; 7) informed consent; and 8) respect
for enrolled participants and communities [13]. Sugar-
man expanded Lo and Grady’s ethical considerations for
HIV cure clinical research to include considerations
for third-party risks, confidentiality and media atten-
tion, and financial aspects [14]. In this paper, we
examine the context of HIV cure clinical research at
the EOL and generate considerations adapted to the
reality of a specific HIV cure clinical research proto-
col called The Last Gift: Development of End-of-Life
Translational Research Model.
Clinical research at the EOL, rapid research autopsy and
gifting relationship
The EOL clinical research literature, particularly in the
oncology field, is rich with considerations of ethical con-
duct of research [11, 12, 27, 28]. Seppet and colleagues,
for example, framed key ethical issues for research with
dying individuals, including recruitment considerations
for terminally ill participants, establishment of inclusion
and exclusion criteria, provisions to ascertain sex and
gender differences, assessment of capacity to provide in-
formed consent, protection of privacy, and biobanking
issues [29]. While the notion of EOL clinical research is
not in itself ethically problematic, it can be difficult to
conduct such research well given the inherent practical
and logistical challenges [30, 31]. For instance, EOL re-
search occurs at the same time as participants and their
loved ones prepare for death [3]. More specific to the
Last Gift study, one methodological issue that arises is
the uncertainty associated with the EOL prognosis [32].
Researchers need to ensure that the timing of research
initiation is right – in this case, when life expectancy is 6
months or less. Should participants live longer than 6
months, the research team should be prepared to follow
the study participants until the EOL. If that is the case,
the Last Gift study procedures do not change, and the
research team continues to follow the Institutional
Review Board (IRB)-approved protocol. The research
team will continue to follow participants as long as
needed. If participants are stable for a long time, how-
ever, the research team may consider increasing the visit
intervals so as to minimize the burden of longitudinal study
participation. This should be done on a case-by-case basis.
Further, the research team should be careful not to induce
death-related distress, meaning that participants would
become anxious consenting for a study that requires a
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dressed by carefully selecting participants who are fully
aware of their prognosis and have accepted the fact that
they are terminally ill.
Another question is the generalizability of EOL scientific
data when most HIV cure-related research is intended for
‘otherwise healthy individuals’ [8]. Generalizability of
study findings from the Last Gift study to all PLWHIV
cannot be ensured due to a small sample size (n = 30) and
confounding factors associated with the various causes of
death. Further, the situation of characterizing the HIV res-
ervoirs of Last Gift participants before and after death is
unique to this specific protocol. However, the overall HIV
reservoir size and composition should not necessarily be
different in PLWHIV at the EOL, particularly in organs
that are not affected by the terminal condition. Although
some results may not be generalizable to the wider popu-
lation of PLWHIV, EOL clinical research may be more
generalizable to the human condition than non-human
animal models, analysis of tissues from repositories with-
out clinical information, or HIV latency in in vitro models
[9]. The Last Gift study team attempts to enhance
generalizability of ante-mortem data by studying clinical
samples collected from otherwise healthy cohorts of indi-
viduals who interrupted ART (as part of ongoing or past
clinical studies). Research findings from blood donations
between the Last Gift and other ART interruption cohort
study participants will be compared. If similar patterns in
the blood are seen, the team will be more confident in
generalizability of findings from the autopsy specimens of
the Last Gift cohort. Generalizability will be harder to
prove for tissue samples, since most cannot be collected
from living individuals.
Another consideration for the case of the Last Gift study
is that participants are enrolled in a clinical study to ad-
vance HIV cure research, and not to advance understand-
ing of the disease they are dying from. This may present
an internal conflict for Last Gift study participants. The
research team addresses this concern by being open to
co-enrollment in other clinical protocols. For example,
one of the Last Gift study participant had a rare
ALS-related condition and donated part of his spinal cord
to a separate research protocol. Last Gift participants can
also co-enroll in the California NeuroAIDS Tissue Net-
work (CNTN) to allow better understanding of mecha-
nisms causing neurological and psychosocial impairments
in HIV infection [33]. At this juncture, however, the Last
Gift study is purely observational which limits potential
study conflicts. Should the Last Gift study include HIV
cure investigational interventions (e.g., broadly neutraliz-
ing antibodies) that affect clinical research findings in the
future, participants may need to choose between enroll-
ment in this HIV cure-related protocol or advancing sci-
ence for the disease that will cause their death. Thespecifics would need to be detailed in the inclusion/exclu-
sion criteria of each clinical research protocol.
While ethical frameworks inform clinical research with
living human participants, ethical guidelines for research
on the recently dead remain limited [34, 35]. The Last
Gift study protocol involves a rapid research autopsy
that must occur within 6 hours of death. Rapid autopsies
are often used in cancer research and allow preservation
of proteins and nucleic acids and access to tissues in-
accessible during life [16, 20]. This means that autopsy
procedures must occur in the emotionally charged envir-
onment shortly following the participant’s passing, and
the family must be willing to let go of the body [16, 36].
Rapid autopsy protocols need to be robust and study
staff must remain continually available. Pentz and col-
leagues further advised that researchers should treat the
body of the newly dead in a dignified manner [35]. For
example, Last Gift always observes a minute of silence at
the beginning of the autopsy to honor the life of each
participant and the gift they gave at death. Invasiveness
should also be minimized and justified in terms of ex-
pected scientific benefits to be generated [35]. Finally,
the ante-mortem wishes of the deceased person should
be respected (see Patient-Participant Centeredness dis-
cussion below) [37].
Moreover, due to the invasive nature of the study in-
vestigating reservoir sites and deep tissues post-mortem,
Last Gift study participants must donate their entire
body after death. The full body donation should not be
confused with traditional organ donation programs [38].
With the passage of the HIV Organ Policy Equity
(HOPE) Act, PLWHIV are now able to donate their
organs. There is a high (79.8%) willingness in this popu-
lation to serve as donors [39]. While traditional organ
donation is intended for future transplantation into
another person, rapid research autopsies use organs and
tissues for basic science research [38]. Thus, Last Gift
study participants enter into an explicit gifting relationship
of their entire body with the study team, other PLWHIV
and the HIV cure research community [38, 40]. In the
United States, the Uniform Anatomical Gift Act (1968,
2006) governs the making of body donations in biomedical
research, and prescribes the conditions by which such gifts
can be made [41]. Purposes of body or organ donation can
include transplantation, therapy, research or education. The
Last Gift study performs a rapid research autopsy and not a
clinical forensic autopsy. No individual autopsy report will
be shared with family member or loved ones, but scientific
results will make sense in the aggregate.
Protecting autonomy through informed consent
Since there is no clinical benefit of participating in the
Last Gift study, a comprehensive informed consent
process that distinguishes between benefits to science
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formed consent process must clearly state that EOL HIV
cure-related research is not curative – neither for HIV nor
the terminal illness – with extreme sensitivity to the lan-
guage used to describe the research [14, 44, 45]. The in-
formed consent process must also convey the research
objectives, methods, procedures, repeatedly emphasize the
right to refuse enrollment or withdraw at anytime, and en-
sure that potential participants understand that their en-
rollment decision will not affect health care services
participants would normally receive [11, 46]. There should
also be a formal assessment of the participant’s compre-
hension about key aspects of the study [13].
In the Last Gift study, the risk of therapeutic miscon-
ception – defined as believing incorrectly that the pri-
mary purpose of research is to provide clinical benefit
rather than advance scientific knowledge [47] – is mini-
mized because participants volunteer for a study distinct
from their terminal illness. Researchers clearly state that
the Last Gift study has absolutely no curative intent, and
research participation is not done out of desperation to
become cured of HIV or the terminal illness. Participa-
tion in the Last Gift study will not extend life further.
Nonetheless, we acknowledge that while therapeutic
misconception might not apply to participants at the
spoken level, it may exist at the unspoken or implicit
level. For example, the need for participants’ social desir-
ability, mediated by altruistic intent, may play an out-
sized role in their decision to participate. In the Last
Gift study, we ensure that volunteers understand they
will not benefit clinically from their participation in re-
search, but their donation will help advance the field of
HIV cure-related research. Horng and Grady used the
term ‘therapeutic optimism’ to describe the hope for best
possible outcomes in clinical research [48]. Therapeutic
optimism is less problematic because it does not com-
promise personal autonomy [48]. In the Last Gift study,
therapeutic optimism should not be directed towards
self given poor prognosis but towards the HIV cure re-
search enterprise as a whole.
Moreover, study candidates should enroll in the Last
Gift study with the capacity to consent for themselves.
Surrogate consent can be problematic and needs careful
consideration [49, 50]. Although current U.S. federal
regulations allow for consent to be obtained from a sur-
rogate, this process is also subject to applicable state and
local regulations. To date, few states have promulgated
specific laws or policies for obtaining surrogate consent
for research, particularly research that does not offer the
prospect of direct therapeutic benefit to the study
participants. Given this unclear regulatory framework,
the potential vulnerability of dying patients, the psycho-
logical and emotional stress associated with making clin-
ical and research decisions at the EOL, and numerousstudies suggesting that surrogates often do not know a
patient’s preferences regarding both clinical treatment
and study participation, the ethical obligation to protect
the rights and wellbeing of study participants suggests
that obtaining proxy consent should be carefully evalu-
ated and discussed on a case-by-case basis.
Of related importance, autonomy is determined by three
conditions: 1) intentionality, 2) understanding, and 3) a
lack of controlling influences [51]. The broader EOL lit-
erature shows concerns about decisional capacity of ter-
minally ill persons, due to the possibility of cognitive
impairment, which can lead to inability to make informed
or rationale choices [46]. Furthermore, HIV-associated
cognitive impairments are common among PLWHIV
[52]. In the Last Gift study, participants are assessed for
cognitive functioning prior to entry to ensure that they are
able to understand the study information and make an in-
formed decision.1 Anecdotally, participation in the Last
Gift study appears to offer participants an opportunity to
exert their self-determination and rise above their circum-
stances despite their imminent death. The Last Gift study
team also helps study participants draft their advance di-
rectives and a copy of these directives are placed in their
study chart. These are important from an ethical stand-
point because they respect the autonomy and dignity of
the participants.
While informed consent can be seen as a static or
one-time event, disease progression is dynamic and may
result in diminished capacity over time [11, 53]. The
Last Gift study team emphasizes informed consent as a
continuous process throughout the entire study and
builds the researcher-participant relationship with care-
ful considerations for the participant’s wishes until the
EOL. For example, Last Gift participants are asked if
they are willing to donate blood until the EOL at each
visit. Beaver and colleagues called this approach ‘process
consent’, allowing for a renegotiation around participa-
tion at different stages of the research interaction [30].
Mackin and colleagues [54] described the process of
adaptation as follows:
“For individuals at the end of life, promoting patient
self-determination requires a climate in which
decision making is both facilitated and adaptive (i.e.,
accommodating to changes in attitudes on the basis of
real-time experiences) at a time when control over various
aspects of life is in decline. Vigilance is required to assure
patients maintain their rights of self-determination for as
long as possible, only relinquishing control to a proxy
who has a deep appreciation of the individual’s values and
desires. This is best accomplished far in advance of serious
declines in personal health, and, practically speaking, prior
to discussions concerning participation in a specific
research protocol.” [Emphasis added]
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EOL stages in the context of research, such as the transi-
tion from primary medical care, to palliative care on to
hospice care, to the dying process, and finally to the
impact of death on the loved ones and next-of-kin (be-
reavement process) [3].
An important aspect of informed consent is ensuring
that the process remains free from coercion or undue
influence [11]. Agrawal defined coercion as “[a] credible
and irresistible force exerted by one person that negatively
limits the options of another person” [12]. Coercion is
thus a relational concept that undermines voluntariness
[12]. For example, the influence of the physician, biomed-
ical HIV cure research team, or family members could cre-
ate pressure to enroll in a clinical study [12]. Labeling
terminally ill patients at the EOL as inherently coerced,
however, may fail to take into consideration the various
pressures that may exist at the EOL. In the Last Gift study,
participants do not enroll out of desperation to be cured
of HIV as most of them have done well on antiretroviral
therapy. Possible ways to reduce coercion would be to en-
sure that the physician taking care of patients at the EOL
would not be the one obtaining informed consent from
candidates to enroll in clinical research, so that the demar-
cation between clinical care and research participation re-
mains clear [12, 54]. Similarly, as part of the Last Gift
study, researchers must be careful not to interfere with
the clinical care team by giving medical advice to study
participants. Of note, the Last Gift researchers and clini-
cians remain separate, and each Last Gift participant has
his/her own clinical team. The Last Gift team does not
provide clinical care, not even palliative care. The Last
Gift team also does not interfere with any medical deci-
sion made by the participant’s clinical care team.
Another method considered by Casarett involves giving
candidates ample time to make decisions over multiple
visits [46]. The informed consent process and research in-
teractions must emphasize the voluntary nature of partici-
pation that can be revoked at anytime and for any reason
without consequences [54]. Further, financial incentives
should not be the primary motivator for participation in
the Last Gift study. The Last Gift study provides modest
compensation for blood draws and supports costs for cre-
mation post-research autopsy if the participant desires.
After extensive discussion with the Community Advisory
Boards and the UCSD IRB, it was deemed that cremation
would not exert an undue inducement in the Last Gift
study, but was a necessity given the invasive nature of re-
search procedures post-mortem. Cremation, however, is
not described as a study benefit.
The Last Gift study team favors shared decision mak-
ing as a way to enhance the recruitment experience for
study participants. Decisions to enter in the study are
understood as a set of interactions with the researchteam, rather than discrete, isolated events [55–58]. The
research team helps Last Gift candidates understand that
a decision should be made, while describing the risks,
benefits, uncertainties and possible options to candi-
dates, to ultimately help them come to a decision [57].
Shared decision making also helps promote trust be-
tween the research team and study participants [56]. As
explained by Epstein and colleagues:
“Engaging patients in constructing preferences in the
face of complexity, inadequate evidence, and
irreducible uncertainty involves more than provision
of information and an invitation to choice. It also
involves dialogue about the communication process
itself; that is, what patients want to know, what
information is relevant, how patients prefer to be
informed, patient’s roles in decision making, and who
else (if anyone) should be present. Seen in this way,
constructing preferences (…) involves building
relationships, providing information, and exploring
preferences, which then strengthen relationships,
understanding, and involvement in decisions” [55].
In such highly innovative HIV cure-related research, in-
vestigators must interact with study participants as true
partners and collaborators in research. In the Last Gift,
participants help investigators answer scientific questions
[43]. Study participants must be able to make decisions
that are free of coercion, manipulation or undue persua-
sion [49].
Avoiding exploitation and fostering altruism
Agrawal defined exploitation as “[t]he unfair distribution
of the benefits and burdens from a transaction” [12].
Protection from exploitation in clinical research is
largely related to the ethical principle of distributive just-
ice, in that the individuals or community taking on the
burden of research derive some sort of compensatory
benefit. Since EOL HIV cure-related research does
not confer direct clinical benefit, a worry arises that
terminally ill PLWHIV are inherently subject to ex-
ploitation [59]. If participants genuinely share the goal
for which research is conducted, as is believed to be
the case of the Last Gift study, the exploitative worry
is diminished [59]:
“If research subjects have genuinely altruistic motives,
that fact can make a direct difference to the ethical
permissibility of a clinical trial: it can remove concerns
about exploitation that would otherwise apply.”
We believe that altruism can remove some concerns
about exploitation that would otherwise apply. As such,
we believe that both avoiding exploitation and fostering
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related research. Hence it is worth exploring the concept
of altruism in the context of the Last Gift study. Lee de-
fined altruism as “unselfish concern for the welfare of
others [60].” Research shows that altruism is not a sole
factor in a person’s decision-making process, but it is
nevertheless important [61]. The literature suggests that
people rarely participate in clinical research out of
purely altruistic reasons. They also hope to personally
benefit from the transaction [61]. Bidad and colleagues
made the distinction between pure altruism (true self-
lessness), hypothetical altruism (stated selfless behavior
but not put to the test), weak altruism (hope to person-
ally benefit), contingent altruism (altruistic behavior con-
tingent upon personal benefits) and sense of duty [61].
While these different types of altruism have oftentimes
been cited reasons to participate in HIV cure clinical re-
search [62–65], altruism has not been well described in
the HIV cure research context. We suggest the need for
further empirical research examining the psychological
characteristics of Last Gift study participants to under-
stand why they decide to participate in EOL HIV
cure-related research and take on additional risks and
burdens for the benefit of others [66]. In particular, al-
truism should be explored as the construct of weighing
societal benefits of research participation above personal
risks and burdens [67]. Understanding altruistic motiva-
tions of PLWHIV at the EOL could help inform recruit-
ment, informed consent, retention and overall study
implementation [38]. Undoubtedly PLWHIV should be
permitted to assume risks to help advance HIV cure sci-
ence. While the presence of altruistic motivations may
reduce concerns of exploitation, there should nonethe-
less be limits placed onto altruism [68]. Różyńska justi-
fied the imposition of limits on risks in clinical research
by the need to protect both the research enterprise and
the study participants [69]. These limits are usually de-
termined by the IRB and regulatory bodies overseeing
clinical research [12]. The study team also has an ethical
responsibility to question why Last Gift participants de-
cide to join the study, and ensure that they do so out of
altruism and for the societal and scientific benefits [38].
Furthermore, even when the nature of a transaction
seems unfair, as in the case of EOL HIV cure-related
research, there is nothing unethical or exploitative in pursu-
ing one’s self-interests. This is particularly true when the
goals are reasonable and altruistic, as is true in this case.
EOL HIV cure-related research has, prima facie, the goal of
improving the lives of future PLWHIV. Moreover, there is a
direct but immeasurable benefit to participants through
their altruistic contributions. Wertheimer acknowledged
this when he wrote that “we need a more protean concep-
tion of what counts as a benefit to A, one that includes A’s
purposes, goals and values [70].” Other philosophers havemade similar arguments, such as Feinberg’s proposition
that the notion of benefit should include “fulfillment of
one’s aims, purposes, or desires, including altruistic and
conscientious ones [71].”
Maintaining a favorable benefits to risks balance
In accordance with the principles of beneficence and
non-maleficence [49], research must be carefully assessed
to ensure that risks remain balanced in relation to benefits
for participants and society [26, 72]. Clinical research
should minimize risks, enhance potential benefits, and en-
sure that risks and burdens are justified in relation to pro-
spective benefits [26]. Benefit-risk assessments can be
challenging, however, because they are contextual and
asymmetric (e.g. risks are often to participants while bene-
fits are to society) [8]. Another challenge is that benefits
and risks may differ from the perspectives of the IRB ver-
sus the participants [8]. Participants may see payments,
services or altruism as benefits, whereas researchers and
IRB members are prohibited from considering them thus.
Further, risks can be relative to a consenting individual’s
current medical condition, like the stage of disease and
care options available [8]. Weijer and Miller called for the
use of a ‘risk-knowledge calculus’ to determine whether
risks of clinical research could be justified [73]. In the Last
Gift study, we must consider what constitutes favorable
benefit-risk ratios for both HIV cure-related research and
PLWHIV at the EOL. Participants have no survival expec-
tations beyond 6 months. Moreover, research information
is not designed to alter disease course or prolong survival,
but contribute to generalizable knowledge about HIV res-
ervoir research [11]. This contrasts to other EOL research
whereby terminally ill patients may be willing to undergo
aggressive and risky investigations with the hope of
prolonging life.
Benefits, risks and burdens of research at the EOL
may also be difficult to define and change over time. For
example, Casarett and Karlawish described participant
goals at the EOL in terms of relief from symptoms, dig-
nity and meaning, social relationships and control [46].
Time spent undergoing blood draws and answering
questionnaires may detract from valuable time with
loved ones [11]. While scientific review committees usu-
ally consider risks in clinical terms, it is important to
pay attention to psychosocial aspects of clinical research
participation at the EOL [11]. Terminally ill persons may
derive tremendous mental and emotional benefits from
research participation, especially when able to make a last-
ing contribution to science [54, 74]. A critical synthesis of
the EOL clinical research literature revealed that most ter-
minally ill clinical study participants viewed the experi-
ence as positive, but a minority experienced minor
psychological distress [27]. Careful selection of EOL study
participants and proactive identification of concerns can
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preliminary experience with the Last Gift study showed
that research participation has been overwhelmingly posi-
tive for participants, more empirical research is needed to
determine how terminally ill PLWHIV experience HIV
cure-related research participation at the EOL in order to
guide investigations and ethics reviews. Such research will
be critical if research teams hope to maintain a favorable
balance of benefits to risks that terminally ill PLWHIV
will also find acceptable [46]. Further, PLWHIV, other ter-
minally ill individuals, and families/loved ones of recently
deceased patients should be included in EOL HIV cure re-
search design and IRB deliberations to help define accept-
able benefits and risks in such research.
One ethical question that arises in the context of the
Last Gift study is whether PLWHIV would be willing to
accept greater risks in order to participate in interven-
tional EOL HIV cure clinical research. While the current
Last Gift study is limited to observational assessments
(e.g. what happens to viral reservoirs when ART is main-
tained or interrupted), PLWHIV may be willing to take
part in experimental research involving immune-based
strategies, latency-reversing agents, or other HIV cure
research approaches tested in non-EOL volunteers. In-
volving terminally ill PLWHIV in interventional HIV
cure research should be considered since first generation
research will likely involve significant toxicities and bur-
dens. Like first generation antiretroviral therapies, their
effectiveness will likely be suboptimal or even harmful.
We propose a benefit-risk assessment framework simi-
lar to the one suggested by DiGiusto and colleagues
[75], which compares the ethical permissibility of testing
HIV cure-related research interventions with PLWHIV
at the EOL (Table 1). Such assessments must take into
consideration the population under study, the risks of
the interventions and other clinical factors [8, 76]. We
believe that latency-reversing agents and immune-based
strategies would have a favorable benefit-risk profile for
PLWHIV at the EOL, while stem cell transplantations
would be unfavorable. An important consideration is
that some interventions are too risky and not adequate
to be offered to terminally ill participants (e.g. stem cell
transplants requiring total ablative chemotherapy and
radiation). Further, long-term safety and effects would
not become manifest with terminally ill participants be-
cause of the short expected life-span. The EOL transla-
tional model, however, might still be useful to evaluate
some parts of an intervention. For example, in the case of
gene editing, while long-term follow-up of study partici-
pants would be needed to test for potential genotoxic ef-
fects, the EOL translational research model could still be
useful to determine how editing techniques can safely be
delivered to cells and tissues – including the brain. Add-
itionally, we believe analytical treatment interruptionswould have a favorable benefit-risk ratio at the EOL and
are already occurring as part of the Last Gift study. For ex-
ample, many PLWHIV at the EOL no longer wish to con-
tinue their ART. For observational studies, however,
terminally ill PLWHIV should not be explicitly asked to
interrupt ART, but should elect to do so on their own.
Some interventional studies – such as those involving
immune-based strategies – may include an analytical
treatment interruption in the study design. Finally, the
physical state of the participant should also be taken into
consideration when undergoing complex blood draws
(e.g., leukaphereses) or other invasive study procedures
(e.g. lumbar punctures and biopsies), and therefore,
case-by-case determinations should be made.Safeguarding against vulnerability through patient-
participant centeredness
The unique circumstances surrounding the EOL period
may imply that some participants are potentially vulner-
able [11]. Vulnerability refers to the “[i]ncreased potential
that one’s interests cannot be protected [12].” In clinical
research, the epithet ‘vulnerable’ denotes specific require-
ments for protecting or safeguarding participants’ safety
and rights. The U.S. Federal regulations for the protection
of human research participants classify children, pregnant
women/fetuses/neonates, prisoners and persons with
mental disabilities as vulnerable [77]. The NIH has also
adopted a broader definition of vulnerability in which ter-
minally ill individuals are also considered a “special class
of research subjects [78].” Interestingly, research with de-
ceased humans does not fall under the technical definition
of research with human participants [34, 77] and the U.S.
Office for Human Research Protections (OHRP) remains
conflicted whether research with the newly dead meets
the technical definition of human research [79].
A number of authors view people at the EOL as inher-
ently vulnerable due to their terminal condition [30, 80, 81].
Other scholars prefer to explicitly define what people are
vulnerable to for the designation to hold salience in the clin-
ical research context [12]. For instance, Kipnis identified six
causes of vulnerability that might interfere with a partici-
pant’s ability to provide informed consent: 1) cognitive, 2)
deferential, 3) medical, 4) juridic, 5), allocational, and 6) in-
frastructural vulnerability [82]. Henry and Scales posed that
terminally ill individuals should be considered vulnerable if
they lack decision-making capacity from cognitive im-
pairment due to an underlying disease, complication or
side-effect of therapy [11]. Moreover, dying individuals can
be vulnerable if their medical state makes them susceptible
to therapeutic misconception out of desperation, as dis-
cussed above [11]. Agrawal recommended that vulnerability
be evaluated on a case-by-case basis, and concluded that it
does not necessarily lead to lack of voluntariness [12].
Table 1 Benefit-Risk Assessment for HIV Cure-Related Research at the EOL
HIV Cure-Related
Research Approaches
Possible Positive Outcomes Potential Risks Benefit-Risk Assessment
for PLWHIV at the EOL
Other Considerations
Latency-reversing agents Stimulation of replication-
competent provirus
from latently-infected
cells and perturbation
of HIV reservoir (although
this has no direct clinical
benefit)
Side effects of latency-
reversing compounds
(various toxicity levels)
Favorable Already being tested in
‘otherwise healthy volunteers’;
long-term effects would not
become manifest
Immune-based strategies
(e.g. broadly neutralizing
antibodies)
Improved immune response
to HIV
Risks of immune-based
approaches, including
potential for
development of
auto-immunity
Favorable Already being tested in
‘otherwise healthy volunteers’;
long-term effects would not
become manifest
Stem cell transplants Modality aims at making cells
resistant to HIV infection
Risks associated
with irradiation and
chemotherapy; hepatic
effects, renal failure, graft-
versus-host-disease
(GVHD); too great to
withstand for PLWHIV at
the EOL
Unfavorable; cannot
be justified in PLWHIV
at the EOL
Not indicated in ‘otherwise
healthy volunteers’; engraftment
and chimerism may not have
time to manifest at the EOL
Gene editing or
modification
Process of editing
deoxyribonucleic acid (DNA)
inside immune cells to make
them less susceptible to HIV
or better able to clear
infected cells
Off-target modifications
or activation of proto-
oncogenes causing
malignancies; other risks
associated with gene
editing
Contingent on the
intervention
Long-term effects would not
become manifest; EOL
translational research model
could still be useful to
determine how gene editing
techniques can be delivered
safely to cells and tissues –
including the brain
Analytical treatment
interruptions
N/A Development of
resistance to ART
regimen; increased risks
of developing
opportunistic infections;
other risks associated
with analytical treatment
interruptions
Favorable Already being conducted in Last
Gift study – in observational
studies, PLWHIV should not be
explicitly asked to interrupt
ART, but should elect to do so
on their own; some
interventional studies (e.g.
immune-based strategies) may
include an analytical treatment
interruption in the design
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categorized as vulnerable simply because they are termin-
ally ill. Instead, the potential for vulnerability should be
carefully evaluated in the clinical research context for each
participant [11, 83, 84]. Further, asking about specific as-
pects of a person or the circumstances that might render
participants vulnerable serves as a basis for ethical and ef-
fective clinical study implementation [85]. Pre-empting
possible causes of vulnerability can lead to improved pro-
tections while avoiding unnecessary barriers to participa-
tion, stereotyping and even stigmatization [84]. In fact,
older PLWHIV who were infected decades ago when HIV
was a death sentence have faced their own imminent mor-
tality once before and are arguably more capable of mak-
ing decisions to enroll in HIV clinical research. To deny
them the opportunity to contribute to HIV cure-related
research at the EOL based on an a priori label of vulner-
ability would seem to be overly paternalistic [27]. The
HIV community dealt with similar issues in the 1980s,when sick participants who did not meet inclusion/exclu-
sion criteria were excluded from early, life-saving HIV
treatment trials. PLWHIV fought for compassionate use
and expanded treatment access, which provided valuable
data in the clinical setting where emerging antiretrovirals
were eventually used.
Moreover, EOL clinical research requires careful de-
sign and execution, as well as sensitivity to participants’
needs [27]. Terminally ill individuals have specific phys-
ical, psychological, social and spiritual needs while pre-
paring for death and achieving life closure [74, 86]. We
believe in the need for patient-participant-centered clin-
ical research with terminally ill PLWHIV. In a study of
patient needs and preferences at EOL, twenty-six (26)
items were considered consistently important, including
pain and symptom management, preparation for death,
achieving a sense of completion, decisions about treat-
ment preferences, and being treated as a whole person
[74]. In a different review, fatigue was the most common
Table 2 Examples of Patient-Participant Centeredness
Considerations for Last Gift Study
EOL Clinical Research Conduct
• Minimize burden of study participation for terminally ill
participants [54]
• Ensure research remains flexible, taking into consideration fatigue
and fluctuating symptoms across disease trajectory [27, 54]
• Assist participants with completion of study procedures and
questionnaires [27]
Quality of Life at the EOL
• Pay attention to quality of life at the EOL [12]. For example, location
of care is an important indicator of quality of EOL care [109].
• Honor treatment preferences of terminally ill individuals, including
pain management and palliative care [110]
• Respect participants’ privacy and need for time with next-of-kin/
loved ones
• Consider participants’ food preferences and other small attentions
• Consider how substance use at the EOL affects study participation
(e.g. alcohol, cannabis)
Advance Care Planning
• Assist participants with advance care planning needs [74]
• Provide proper referral and counseling for participants who desire
medical aid to end life under California End of Life Option Act
(EOLOA) of 2016
Mental Health, Cultural and Spiritual Issues
• Provide adequate psychosocial support to study participants. The
Last Gift study team has a two psychiatrists and one licensed
psychologist on staff.
• Give consideration to mental health issues of participants, including
fear, suicide ideation, depression, among others [28]
• Pay attention to cultural issues, spiritual well-being and meaning as
integral to the dying process [3, 28]
Financial and Legal Issues
• Pay attention to issues around the burden of cost of dying and
health insurance
• Help ensure participants have support for EOL legal needs [111]
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20 to 60% PLWHIV in the general population [3]. Pain
is also a symptom that has received attention in research
with PLWHIV [87]. A systematic review of 61 studies
found that the prevalence of pain (defined operationally
as a symptom) among PLWHIV ranges from 54 to 83%
[88]. Fatigue and pain are likely to be exacerbated when
coupled with a terminal illness. In addition to fatigue
and pain, mental health burdens [89], social isolation
[90, 91], insomnia [92] and body image issues [93, 94]
may be of great import to PLWHIV. Depression, in par-
ticular, is of clinical relevance and may need careful
evaluation and treatment, beyond the provision of psy-
chosocial support [95, 96]. Further, our experience re-
veals that some interviews with terminally ill PLWHIV
require frequent interruptions, with hospice nurses com-
ing in and out, and participants asking for various items.
Study staff must remain extremely flexible when con-
ducting HIV cure-related research with PLWHIV at
the EOL.
An issue that has emerged in the Last Gift study is the
necessity to maintain boundaries between the Last Gift
team and the study participants, and to maintain good
communication with clinical teams and providers. The
Last Gift team spends a lot of time with study partici-
pants and often create special bonds with each of them.
As a consequence, Last Gift participants trust the re-
search team and discuss very intimate thoughts, con-
cerns and wishes [97]. The Last Gift team observes
participant centeredness by bringing favorite foods and
providing other small attentions to study participants.
This shows the appreciation, reverence, gratitude and re-
spect the research team has for the participants. None of
these niceties are presented as benefits of the study to
the participants but are considered small tokens of ap-
preciation for their altruism and acknowledgements of
scientific contributions.
Another point of considerations is the need to not be
overbearing with study procedures, especially at the very
end of life. For example, the Last Gift protocol indicates
blood collections as close to death as possible. We spe-
cifically ask study participants early on if they are willing
to donate blood until the very EOL, including when they
will be sedated or on life support. We must also ensure
that the next-of-kin/loved ones feel comfortable honor-
ing the Last Gift participants’ wishes until the EOL. Our
experience has shown that it takes a very close relation-
ship and sensitive approach to accomplish this without
seeming too intrusive. Further, drawing blood at the EOL
may present challenges, since terminally ill people may be
dehydrated, with low blood pressure, or fragile veins.
Table 2 describes possible examples of patient-
participant-centeredness considerations for the Last Gift
study (note: this list is not exhaustive).The California End of Life Option Act (EOLOA) went
into effect in June 2016, creating a process for dying pa-
tients to ask doctors for a prescription for medical
aid-in-dying that patients can ingest privately at home
[98]. Like laws in six other U.S. states and the District of
Columbia, the California EOLOA gave mentally capable,
terminally ill adults with 6 months of less to live the op-
tion to request medications to end unbearable suffering
and die peacefully. Although the future of this law is un-
certain [99, 100] and it is beyond the scope of this paper
to discuss the ethics of medical aid to end life, we ac-
knowledge ethical tensions related to individual auton-
omy versus paternalism, the nature of the patient-
physician relationship, trust in that relationship and the
medical profession, and the role of the medical profes-
sion in society [101]. In a study of 70 patients receiving
palliative care for advanced cancer, 73% believed that
Table 3 Ethical Considerations for HIV Cure-Related Research at the End of Life
Themes Considerations
EOL clinical research, rapid research autopsy
and gifting relationship
The research team should:
• Anticipate issue of prognostic uncertainty, including ensuring that timing of research initiation is
right and be prepared in case participants live longer than 6 months.
• Maximize generalizability of EOL scientific data to HIV cure-related research field.
• Allow co-enrollment in another research protocol to help advance science for disease
participants are dying of, provided there is no inclusion/exclusion criteria conflict.
• Follow established guidelines related to rapid research autopsy, including: having staff available
at all times, treating the body of the deceased in a dignified manner, minimizing and justifying
degree of invasiveness in relation to the expected scientific benefits, and respecting pre-mortem
wishes of Last Gift study participants.
Protecting autonomy through informed
consent
• The informed consent process must clearly state that EOL HIV cure-related research will not be
curative, and must convey the research objectives, methods, procedures, decision will not affect
medical care, and right to refuse enrollment or withdraw from research at anytime.
• Last Gift study participants should consent for themselves and participants should be assessed
for cognitive functioning.
• Last Gift study team should view the informed consent process as continuous and carefully
consider Last Gift participants’ wishes until the EOL (e.g., process consent) or advance directives.
• The informed consent process must remain free from coercion, or undue influence or persuasion.
Possible ways to reduce coercion include: 1) physician taking care of patient should not provide
consent to enroll in Last Gift study, 2) decisions should be made over multiple visits; 3) research
team should emphasize voluntary nature of research; 4) financial incentives should not be primary
motivator to participate.
• Shared decision making should be used as a way to enhance the recruitment experience,
promote trust and view participants as true partners in research.
• The risk of therapeutic misconception should be minimized.
• For additional considerations, see [12].
Avoiding exploitation and fostering altruism • Protection from exploitation relates to the principle of distributive justice, in that there should be
fair distribution of the benefits and burdens from the transaction.
• The Last Gift study team should ensure that participants have genuinely altruistic motives for
participation and understand that they are entering a gifting relationship.
• Further empirical research is needed to examine the role of altruism and psychological
characteristics of Last Gift study participants to understand their decisions to participate in EOL
HIV cure-related research.
• IRBs and regulatory bodies should place limits on ethically permissible risks of clinical research to
protect the HIV cure-related research enterprise.
Maintaining a favorable benefits to risks
balance
• EOL HIV cure research should minimize risks, enhance potential benefits, and ensure that risks and
burdens are justified in relation to prospective benefits.
• A favorable risk-knowledge balance should be obtained, since EOL HIV cure research will not alter
disease course or prolong survival.
• The research team should pay attention to evolving participant goals, including relief from
symptoms, dignity and meaning, social relationships, and other possible psychosocial risks and
benefits.
• More empirical research is needed to determine how terminally ill PLWHIV view acceptable
benefits and risks.
• PLWHIV as well as terminally ill individuals and families/loved ones of recently deceased patients
should be included in protocol design and during ethics reviews.
• Benefit-risk assessments should take into considerations the risks of HIV cure research
interventions and other clinical factors. In general, latency-reversing agents and immune-based
strategies have a favorable benefit-risk balance, while stem cell transplantation do not. The EOL
translational model could be helpful in evaluating components of gene modification and editing
(e.g. safe delivery to cells and tissues – including the brain).
• Analytical treatment interruptions can be ethically permissible at the EOL; however, participants
should elect to interrupt beneficial ART on their own for observational studies. Some
interventional study designs may warrant analytical treatment interruptions.
Safeguarding against vulnerability through
patient-participant centeredness
• Vulnerability implies the need for specific protection or safeguards.
• Last Gift participants should not be categorized as vulnerable simply because they are terminally
ill. Rather, attention should be paid to what participants may be vulnerable to, and adequate
protections should be put in place to alleviate possible sources of vulnerabilities.
• Research with terminally ill PLWHIV requires careful design and execution, and incorporate
sensitivity to participants’ needs, including physical, psychological, mental, spiritual and social
needs (see Table 2). For example, researchers should pay attention to issues related to depression,
social isolation, insomnia, and body image that may be of import to PLWHIV.
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Table 3 Ethical Considerations for HIV Cure-Related Research at the End of Life (Continued)
Themes Considerations
• Appropriate boundaries should be maintained between the Last Gift team and the study
participants. Special attentions such as special foods should not be presented as study benefits,
but as tokens of appreciation, reverence, gratitude and respect.
• The research team should be careful to not be intrusive while attempting to honor the
participants’ wishes until the very EOL.
Ensuring acceptance of loved ones and
community
• The research team should ensure acceptability of the research from next-of-kin/loved ones, and
clarify the role of next-of-kin/loved ones in study participation. Next-of-kin/loved ones should also
be briefed on the study to be willing to let go of the Last Gift participants’ body at the time of
death. The research team should actively support and (if needed) protect next-of-kin/loved ones,
and account for the fact that next-of-kin/loved ones arrangements may be untraditional for
PLWHIV.
• The research team should be sensitive to socio-cultural issues. Extensive and ongoing community
consultation should take place before, during and after the study.
• More empirical research is needed to better understand the perceptions of next-of-kin/loved ones
and community stakeholders around HIV cure-related research at the EOL.
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would consider it if symptoms became insufferable, and
12% would have made the request at the time of the
interview [102]. The main reason for favorably viewing
medical aid to end life was the relief provided by a
straightforward death [102]. The End of Life Option Act
creates an ethical tension for Last Gift study participants
who desire such prescription, as the decision to die must
not be done autonomously and independently but must
also not be coerced or made under undue influence. The
study team should also be prepared to properly consult
and refer Last Gift participants if they ask for such
provision. Given the nature of the rapid research autopsy,
participants’ intentions should also be made known to the
next-of-kin/loved ones and/or the study team.
Ensuring acceptance of next-of-kin/loved ones and
community
In addition to safeguarding patient-participant centered-
ness, it is important to ensure acceptability of the re-
search from next-of-kin/loved ones and the broader
community. By next-of-kin/loved ones, we mean signifi-
cant others, family members, friends and close acquain-
tances of Last Gift study participants. By community, we
mean “a group of people with diverse characteristics
who are linked by social ties, share common perspec-
tives, and engage in joint action in geographical loca-
tions or settings” [103], such as the broader community
of PLWHIV.
As our study team experienced, next-of-kin/loved ones
often have a significant role to play in decision-making and
research participation [17]. We believe next-of-kin/loved
ones should be informed of the participants’ wishes and we
should clarify their role in the study [16, 104–107]. For ex-
ample, our research plan clearly states that consent for
blood draws and rapid research autopsy will be discussed
with a next-of-kin/loved ones in order to minimize con-
cerns or conflicts during the research and at the time ofdeath. Optimally, the research context should go beyond
minimizing concerns and conflicts with the research, to
also actively providing support and protecting next-of-kin/
loved ones. We also acknowledge that the notion of
next-of-kin/loved ones may include untraditional arrange-
ments for PLWHIV.
Further, our study includes a socio-behavioral sciences
component with next-of-kin/loved ones of Last Gift par-
ticipants to assess perceptions and attitudes towards the
study. This activity occurs twice during the study: 1)
shortly after the Last Gift study participants enroll in the
study, and 2) shortly following death. This provides an
opportunity to talk about loss and the bereavement
process, meaning of study participation, any logistical or
practical issue encountered and ways to improve the
conduct of the study. The Last Gift study team takes
care of logistical and administrative items (e.g., transpor-
tation, vital statistic worksheet, death certificates) to take
stress away from next-of-kin/loved ones during difficult
times. We also provide appreciation letters to next-
of-kin/loved ones after the study has ended. The Last
Gift team also tries to follow-up with the next-of-kin/
loved ones after death to make sure they are recovering
and have adequate social support.
Finally, we must be sensitive to socio-cultural issues
and ensure community acceptance around the study.
Following Good Participatory Practice [108], our team
conducted extensive consultation sessions with the
UCSD AntiViral Research Center Community Advis-
ory Board, the Palm Springs HIV and Aging Research
Project and the Palm Springs Positive Life Program
prior to study initiation. There was unanimous ap-
proval of the project by various groups and an overall
community willingness to support the study. Such
community interactions will be ongoing and eventu-
ally involve data dissemination. We will focus on de-
scribing how participation in research contributes to
advancing HIV cure science.
Dubé et al. BMC Medical Ethics           (2018) 19:83 Page 13 of 16Conclusions
In sum, we examined considerations for the ethical con-
duct of EOL HIV cure-related research. The Last Gift study
at UCSD enrolls terminally ill PLWHIV who have a prog-
nosis of less than 6 months and desire to contribute to
HIV cure-related research. Ethical considerations spanned
five domains: 1) protecting autonomy through informed
consent, 2) avoiding exploitation and fostering altruism; 3)
maintaining a favorable benefits/risks balance, 4) safe-
guarding against vulnerability through patient-participant
centeredness, and 5) ensuring acceptance of next-of-kin/
loved ones and community stakeholders. Our consider-
ations are summarized in Table 3; issues described are not
comprehensive. Further exploration is needed regarding
what the fair selection of participants and independent re-
view would mean for HIV cure-related research towards
the EOL. We also strongly advocate for the critical need to
include bioethicists and social-behavioral scientists on
biomedical HIV cure research teams.
Clinical research is essential to advancing science and
medical care. Terminally ill PLWHIV should not be
denied the opportunity to participate in important HIV
cure clinical research opportunities. Once faced with
imminent death when HIV was untreatable, several
PLWHIV now desire to give back to the field of HIV
research. They find a deep sense of purpose and tremen-
dous meaning in death and in leaving a legacy. EOL HIV
cure-related research can be done ethically and effectively
by proactively anticipating key issues that may arise. While
not unique to the fields of EOL or HIV cure research, con-
siderations highlighted can help us support a new research
approach. We must honor the lives of PLWHIV whose in-
volvement in research can provide the knowledge needed
to achieve the dream of making HIV infection curable.
Endnotes
1The Last Gift study team follows the guidelines estab-
lished by the Task Force for Recommending Procedures for
Determination of Decisional Capacity in Subjects Partici-
pating in Research Protocols that included the following
members: Dilip Jeste, MD (Chair), David Braff, MD, Daniel
Masys, MD, Barton Palmer, PhD, Martin Paulus, MD,
Lucille Pearson, and Larry Schneiderman, MD. This Task
Force was convened by Lew Judd, MD, Chairman of
UCSD’s Department of Psychiatry at the request of the
UCSD Human Research Protections Program.
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